D008231DisordersC15.378.553.546.605C20.673.62710110.995397LymphopeniaFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson20580848McIver Z, Stephens N, Grim A, Barrett AJBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow TransplantationMcIver Z, Stephens N, Grim A, Barrett AJ. Rituximab administration within 6 months of T cell-depleted allogeneic SCT is associated with prolonged life-threatening cytopenias. Biol Blood Marrow Transplant. 2010 Nov; 16(11):1549-56.Biol Blood Marrow Transplant2010-05-24T00:00:002010Rituximab administration within 6 months of T cell-depleted allogeneic SCT is associated with prolonged life-threatening cytopenias.BiochemistryNeurologyWake Forest School of MedicineDavidCaudellDavid L. Caudell DVM, PhD36.08943500000000-80.268632000000001400Caudell, DavidAssociate ProfessorGregoryHawkinsGregory A. Hawkins PhD36.09040200000000-80.26700599999999308Hawkins, GregoryProfessorHeidiKlepinHeidi D. Klepin MD, MS36.08919100000000-80.26677800000000343Klepin, HeidiProfessorLanceMillerLance D. Miller PhD, MS36.09032400000000-80.26649100000000574Miller, LanceAssistant Professor28495639Alistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, Cameron A, Leyendecker J, D'Agostino R, Topaloglu U, Boteju LW, Boteju AR, Shorr R, Zachar Z, Bingham PM, Ahmed T, Crane S, Shah R, Migliano JJ, Pardee TS, Miller L, Hawkins G, Jin G, Zhang W, Pasche BThe Lancet. OncologyAlistar A, Morris BB, Desnoyer R, Klepin HD, Hosseinzadeh K, Clark C, Cameron A, Leyendecker J, D'Agostino R, Topaloglu U, Boteju LW, Boteju AR, Shorr R, Zachar Z, Bingham PM, Ahmed T, Crane S, Shah R, Migliano JJ, Pardee TS, Miller L, Hawkins G, Jin G, Zhang W, Pasche B. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial. Lancet Oncol. 2017 06; 18(6):770-778.Lancet Oncol2017-05-08T00:00:002017Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.CarynMorseCaryn G. Morse MD, MPH36.09032400000000-80.266491000000002104Morse, CarynAssistant Professor18208758Morse CG, Kovacs JAEnfermedades infecciosas y microbiologia clinicaMorse CG, Kovacs JA. HIV-infected immunologic non-responders: can we provide a helping hand? Enferm Infecc Microbiol Clin. 2008 Jan; 26(1):1-3.Enferm Infecc Microbiol Clin2008-01-01T00:00:002008HIV-infected immunologic non-responders: can we provide a helping hand?30996137Lisco A, Wong CS, Lage SL, Levy I, Brophy J, Lennox J, Manion M, Anderson MV, Mejia Y, Grivas C, Mystakelis H, Burbelo PD, Perez-Diez A, Rupert A, Martens CA, Anzick SL, Morse C, Chan S, Deleage C, Sereti IJCI insightLisco A, Wong CS, Lage SL, Levy I, Brophy J, Lennox J, Manion M, Anderson MV, Mejia Y, Grivas C, Mystakelis H, Burbelo PD, Perez-Diez A, Rupert A, Martens CA, Anzick SL, Morse C, Chan S, Deleage C, Sereti I. Identification of rare HIV-1-infected patients with extreme CD4+ T cell decline despite ART-mediated viral suppression. JCI Insight. 2019 04 18; 4(8).JCI Insight2019-04-18T00:00:002019Identification of rare HIV-1-infected patients with extreme CD4+ T cell decline despite ART-mediated viral suppression.22Associate ProfessorInternal Medicine, Hematology & OncologyPathology, Comparative Medicinetrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1Associate ProfessorAssociate Professor22613470Puthiyaveetil AG, Heid B, Reilly CM, HogenEsch H, Caudell DLExperimental hematologyPuthiyaveetil AG, Heid B, Reilly CM, HogenEsch H, Caudell DL. A NUP98-HOXD13 leukemic fusion gene leads to impaired class switch recombination and antibody production. Exp Hematol. 2012 Aug; 40(8):622-33.Exp Hematol2012-05-18T00:00:002012A NUP98-HOXD13 leukemic fusion gene leads to impaired class switch recombination and antibody production.0.5022840.038799110research area of0.7136110.06490548subject area for